Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Retained Earnings (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Retained Earnings for 11 consecutive years, with -$822.4 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 17697.01% to -$822.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$822.4 million through Dec 2025, down 17697.01% year-over-year, with the annual reading at -$822.4 million for FY2025, 17697.01% down from the prior year.
  • Retained Earnings for Q4 2025 was -$822.4 million at Cartesian Therapeutics, down from -$729.8 million in the prior quarter.
  • The five-year high for Retained Earnings was -$4.6 million in Q4 2022, with the low at -$822.4 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$343.0 million, with a median of -$412.8 million recorded in 2021.
  • The sharpest move saw Retained Earnings skyrocketed 98.94% in 2022, then tumbled 17697.01% in 2025.
  • Over 5 years, Retained Earnings stood at -$430.3 million in 2021, then surged by 98.94% to -$4.6 million in 2022, then decreased by 0.92% to -$4.6 million in 2023, then fell by 0.46% to -$4.6 million in 2024, then crashed by 17697.01% to -$822.4 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$822.4 million, -$729.8 million, and -$693.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.